Research Papers:
SHARPIN stabilizes estrogen receptor α and promotes breast cancer cell proliferation
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1945 views | HTML 3297 views | ?
Abstract
Ting Zhuang1,2,*, Sifan Yu1,2,3*, Lichen Zhang1,2,4*, Huijie Yang1,2, Xin Li1,2, Yingxiang Hou1,2, Zhenhua Liu1,2,5, Yuanyuan Shi1,2, Weilong Wang6,7, Na Yu6,7, Anqi Li1,2,8, Xuefeng Li9, Xiumin Li6,7, Gang Niu10,11,12, Juntao Xu10,11,12, Muhammad Sharif Hasni12,13, Kun Mu14, Hui Wang1,2 and Jian Zhu1,2,15
1Research Center for Immunology, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, China
2Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, China
3Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Renal Cancer and Melanoma, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China
4Laboratory of Genetic Regulators in the Immune System, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, China
5Synthetic Biology Remaking Engineering and Application Laboratory, School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, Henan, China
6Department of Gastroenterology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
7Center for Cancer Research, Xinxiang Medical University, Xinxiang, Henan, China
8School of International Education, Xinxiang Medical University, Xinxiang, Henan, China
9Department of Medical Oncology, The First Affiliated Hospital, University of South China, Hengyang, Hunan, China
10Department of Cancer genomics, LemonData biotech (Shenzhen) Ltd, Shenzhen, Guangdong, China
11Phil Rivers Technology (Beijing) Ltd. Beijing, China
12Institute of Biochemistry University of Balochistan, Quetta, Pakistan
13Department of Hematology and Transfusion Medicine, Lund University, Lund, Sweden
14Department of Pathology, School of Medicine, Shandong University, Jinan, Shandong, China
15Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
*Ting Zhuang, Sifan Yu and Lichen Zhang contribute equally to this study
Correspondence to:
Jian Zhu, email: [email protected]
Ting Zhuang, email: [email protected]
Hui Wang, email: [email protected]
Kun Mu, email: [email protected]
Keywords: SHARPIN, ER alpha, breast cancer, ubiquitination, protein stability
Received: May 17, 2017 Accepted: June 29, 2017 Published: August 19, 2017
ABSTRACT
Estrogen receptor α is expressed in the majority of breast cancers and promotes estrogen-dependent cancer progression. In our study, we identified the novel E3 ubiquitin ligase SHARPIN function to facilitate ERα signaling. SHARPIN is highly expressed in human breast cancer and correlates with ERα protein level by immunohistochemistry. SHARPIN expression level correlates with poor prognosis in ERα positive breast cancer patients. SHARPIN depletion based RNA-sequence data shows that ERα signaling is a potential SHARPIN target. SHARPIN depletion significantly decreases ERα protein level, ERα target genes expression and estrogen response element activity in breast cancer cells, while SHARPIN overexpression could reverse these effects. SHARPIN depletion significantly decreases estrogen stimulated cell proliferation in breast cancer cells, which effect could be further rescued by ERα overexpression. Further mechanistic study reveals that SHARPIN mainly localizes in the cytosol and interacts with ERα both in the cytosol and the nuclear. SHARPIN regulates ERα signaling through protein stability, not through gene expression. SHARPIN stabilizes ERα protein via prohibiting ERα protein poly-ubiquitination. Further study shows that SHARPIN could facilitate the mono-ubiquitinaiton of ERα at K302/303 sites and facilitate ERE luciferase activity. Together, our findings propose a novel ERα modulation mechanism in supporting breast cancer cell growth, in which SHARPIN could be one suitable target for development of novel therapy for ERα positive breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20368